<DOC>
	<DOCNO>NCT00533169</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose drug ZactimaTM ( ZD6474 ) patient neuroblastoma medulloblastoma gotten bad , come back , respond treatment . Primary Objective : -To determine pharmacokinetics , safety , dose-limiting toxicity , maximum tolerate dose ZD6474 , alone child medulloblastoma , alone combination retinoic acid , patient relapse refractory neuroblastoma . Secondary Objective : -To assess progression-free survival ( PFS ) objective tumor response rate child relapse refractory neuroblastoma medulloblastoma treat ZD6474 +/- retinoic acid context Phase I trial .</brief_summary>
	<brief_title>ZD6474 Alone Combination With Retinoic Acid Pediatric Neuroblastoma</brief_title>
	<detailed_description>The Study Drugs : ZD6474 drug slow function protein tumor cell call protein tyrosine kinase . Tyrosine kinases normally cause tumor cell grow . It think anti-cancer effect give without chemotherapy drug . Isotretinoin show help stop growth neuroblastoma cell . It help cell look normal grow slowly . Study Drug Dose Level Drug Administration : There 3 part study . If medulloblastoma , assign Part A . If neuroblastoma , assigned Part A , Part B , Part C. In Part A , participant receive study drug ZD6474 alone . In Part B portion , participant receive ZD6474 along isotretinoin . In Part C , additional number participant enrol receive ZD6474 along isotretinoin high dose level find Part B . Part A Treatment : Participants Part A take ZD6474 daily mouth form pill liquid 28 day . This 28-day period call study `` cycle . '' In Part A , study drug give different dos . Three ( 3 ) participant enrol dose level . New group continue enrol high dos intolerable side effect see . If assign Part A , dose assign depend number participant enrol side effect may experience . Part B Treatment : Once high tolerable dose ZD6474 find , participant begin enrol Part B . Participants Part B take ZD6474 daily mouth form pill liquid Days 2-28 28-day cycle . Participants also take isotretinoin mouth 2 time day every day 2 week row , point 28-day cycle . Part C Treatment : In Part C , participant follow schedule Part B . Drug Diary ( participant ) : You give `` diary '' record take study drug . You need bring diary study visit . At visit , also ask side effect may experience . Study Visits ( participant ) : During first 2 month study , study visit weekly . After first 2 month , study visit least 1 time month . At visit , follow test procedure perform : - Your complete medical history record . - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . Before cycle , blood collection use blood clotting test . Once month , routine blood/urine test include pregnancy test woman able child . - You ask drug may take able maintain healthy diet . Before every cycle , follow test procedure perform : - You may CT scan , MRI scan , and/or bone scan check status disease . - You may bone marrow aspiration bone marrow biopsy check status disease . - If neuroblastoma , may MIBG scan check status disease . - If neuroblastoma , urine collect test HVA VMA level . Once week Weeks 1 , 2 , 4 , 9 , 13 , 7 day every cycle , ECGs make sure heart remain healthy . Before cycle , urine collect routine test ECHO make sure heart remain healthy . Pharmacokinetic Testing : Extra blood sample draw study pharmacokinetic ( PK ) test . PK test use measure amount study drug blood . The amount blood draw 1/2 teaspoon time . Blood drawn PK test follow time point : - On Day 1 Cycle 1 , 6 hour take ZD6474 - On Days 2 , 8 , 15 22 Cycle 1 take ZD6474 - On Days 1 , 8 15 Cycle 2 take ZD6474 - On Day 1 Cycles 4 , 6 , 8 take ZD6474 If 1 first 3 participant enrol study , blood drawn 2 , 4 , 6 , 8 12 24 hour first dose Cycle 1 . Length Study : You may remain study long benefitting . You take study early disease get bad intolerable side effect occur . End-Of-Study Visit : Once study , end-of-study visit . At visit , follow test procedure perform . If test procedure perform last month , repeat . - Your complete medical history record . - You ask drug may take . - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . - You ECHO . - You ECG . - You may CT scan , MRI scan , and/or bone scan check status disease . - You may bone marrow aspiration bone marrow biopsy check status disease . - If neuroblastoma , MIBG scan check status disease . - If neuroblastoma , urine collect test HVA VMA level . Follow-up Visits : You follow-up visit every month study . These visit continue indefinitely . At visit , follow test procedure perform . - Your complete medical history record . - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . This investigational study . ZD6474 FDA approve treatment follicular , medullary , anaplastic , locally advanced metastatic papillary thyroid cancer . Isotretinoin FDA approve acne . The use drug disease use drug together investigational . Up 66 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . Provision inform consent subject legal guardian 2 . Patients must histologic verification neuroblastoma , ganglioneuroblastoma , ganglioneuroma , and/or demonstration tumor cell bone marrow increase urinary catecholamine ( Vanillylmandelic Acid ( VMA ) and/or Homovanillic Acid ( HVA ) ) , OR histologic verification medulloblastoma , AND progress standard therapy , relapse standard therapy , standard curative therapy know . 3 . Measurable evaluable disease presence within 4 week onset study therapy : a. measurable tumor magnetic resonance imaging ( MRI ) , compute tomography ( CT ) scan Xray obtain prior study entry . Patients appear residual stable tumor upon completion frontline therapy must undergo biopsy document presence viable neuroblastoma medulloblastoma . If active target lesion radiate patient stable disease , biopsy must do least 4 week radiation complete must demonstrate viable tumor , OR 4 . ( Co n't # 3 ) : Evaluable disease document bone marrow obtain prior study entry tumor cell see routine morphology ( Neuron Specific Enolase ( NSE ) stain ) aspirate and/or biopsy OR 5 . ( Co n't # 3 ) ( neuroblastoma patient ) Evaluable disease document MIBG ( metaiodobenzylguanidine ) scan bone scan obtain within 4 week prior study entry positive uptake minimum one site . Patients appear residual stable MIBG positive lesion upon completion frontline therapy must undergo biopsy document presence viable neuroblastoma . If patient one MIBG positive lesion lesion radiate , biopsy must do least 4 week radiation complete must demonstrate viable neuroblastoma . 6 . Performance status Lansky play karnofsky score &gt; / = 40 7 . Age &gt; /=2 year time enrollment 1 . Lab result : ) Absolute neutrophil count ( ANC ) &lt; 750/mm^3 , hemoglobin &lt; 7.0 g/dL , platelet &lt; 20,000/mm^3 ( hemoglobin platelet may support transfusion ) ; b ) Serum bilirubin &gt; 1.5 * institutional upper limit normal ( IULN ) ; c ) Serum creatinine &gt; 1.5 * per IULN creatinine clearance &lt; equal 70 ml/min/1.73m^2 ; ) Potassium , &lt; 4.0 mmol/L despite supplement ; Serum calcium ionize calcium &gt; IULN ; Magnesium normal range per institutional guideline despite supplement ; e ) ALT &gt; 2.5 * IULN alkaline phosphatase ( ALP ) &gt; 2.5 * IULN &gt; 5 * IULN judge investigator relate liver metastases 2 . Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol . 3 . History symptomatic medically manage arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) ( &gt; /= National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade 3 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation control medication exclude . 4 . Previous history Corrected QT ( QTc ) prolongation result medication require discontinuation medication . 5 . Congenital long QT syndrome , 1st degree relative unexplained sudden death 40 year age . 6 . Presence leave bundle branch block 7 . QTc Bazett 's correction unmeasurable , &gt; /=480 msec screen Electrocardiography ( ECG ) . If patient QTc &gt; /=480 msec screen ECG , screen ECG may repeat twice ( least 24 hour apart ) . The average QTc three screen ECGs must &lt; 480 msec order patient eligible study . 8 . Use concomitant medication may cause QTc prolongation , induce Torsades de Pointes induce CYP3A4 function 9 . Clinically significant cardiac event myocardial infarction , TIA , CVA within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia . 10 . Hypertension &gt; 95th percentile age ( either systolic diastolic ) &gt; 140/90 patient &gt; 18 year age uncontrolled oral medication onset study therapy . 11 . Currently active diarrhea may affect ability patient absorb ZACTIMA . 12 . Women currently pregnant breastfeed . 13 . Receipt investigational agent within 14 day prior commence study treatment , prior receipt ZACTIMA time 14 . Last dose prior chemotherapy discontinue less 2 week start study therapy . 15 . Last radiation therapy within last 4 week start study therapy , except palliative radiotherapy nonindex lesion 16 . Any unresolved nonhematologic toxicity great CTC grade 1 previous anticancer therapy , except platinuminduced hearing loss . 17 . Any evidence active graft versus host disease stem cell transplant . 18 . Major surgery within 4 week , incompletely heal surgical incision start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>ZD6474</keyword>
	<keyword>Zactima</keyword>
	<keyword>Isotretinoin</keyword>
	<keyword>13-Cis Retinoic Acid</keyword>
	<keyword>Accutane</keyword>
	<keyword>Pediatric Neuroblastoma</keyword>
</DOC>